13.28

7.70% 0.95

After Hours: 13.21 -0.07 -0.53%

Contineum Therapeutics Inc (CTNM)

Overview News Price History Discussions Forecast

Contineum Therapeutics Inc stock is traded at $13.28, with a volume of 116.58K. It is up +7.70% in the last 24 hours and down -15.84% over the past month. Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Previous Close:

$12.33

Open:

$12.46

24h Volume:

116.58K

Relative Volume:

0.41

Market Cap:

$495.82M

Revenue:

$50.00M

Net Income/Loss:

$-59.98M

P/E Ratio:

-6.0817

EPS:

-2.1836

Net Cash Flow:

$-55.54M

1W Performance:

+8.67%

1M Performance:

-15.84%

6M Performance:

+22.28%

1Y Performance:

+67.89%

1-Day Range:

$12.46

$13.59

1-Week Range:

$11.80

$13.59

52-Week Range:

$3.35

$16.33

Contineum Therapeutics Inc Stock (CTNM) Company Profile

Name

Contineum Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

(858) 333-5280

Address

3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CTNM's Discussions on Twitter

Compare CTNM vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTNM Contineum Therapeutics Inc	13.28	460.35M	50.00M	-59.98M	-55.54M	-2.1836
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-13-25	Initiated	Leerink Partners	Outperform
Sep-25-25	Initiated	Leerink Partners	Outperform
Jun-20-25	Initiated	William Blair	Outperform
Oct-22-24	Initiated	Robert W. Baird	Outperform
Apr-30-24	Initiated	Morgan Stanley	Overweight
Apr-30-24	Initiated	RBC Capital Mkts	Outperform
Apr-30-24	Initiated	Stifel	Buy

View All

Contineum Therapeutics Inc Stock (CTNM) Latest News

Mar 25, 2026

Contineum Therapeutics (NASDAQ:CTNM) Trading 8.7% HigherStill a Buy? - MarketBeat

Mar 25, 2026

Mar 22, 2026

Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Mar 22, 2026

Mar 19, 2026

Bond Watch: Will Corvus Pharmaceuticals Inc stock go up in YEAR2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn

Mar 19, 2026

Contineum Therapeutics, Inc.Common stock (NQ: CTNM - The Chronicle-Journal

Mar 19, 2026

Mar 17, 2026

Revenue Check: Is FKWL still a buy after recent gainsStock Surge & Detailed Earnings Play Alerts - baoquankhu1.vn

Mar 17, 2026

Mar 16, 2026

Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference - Defense World

Mar 16, 2026

Mar 15, 2026

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 13, 2026 - BioSpace

Mar 15, 2026